DocumentsDate added
Original article:
Badyal Ashima1,*, Pandey Rajesh2, Sodhi KS2, Singh Jasbir4.
Affiliation:-
1Registrar, Department of Biochemistry, GMC, Jammu, J&K, India
2Professor,3Professor and Head, Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
The name of the department(s) and institution(s) to which the work should be attributed:
1. Department of Biochemistry, GMC, Jammu, J&K, India
2. Department of Biochemistry, MMIMSR, Mullana, Ambala, Haryana, India
*To whom it corresponds:-
Dr. Ashima Badyal.
214-A Shastri Nagar, Jammu, J&K State, India- 180004
Contact no: +91-9796825414+91-9796825414 .
Abstract:
Context: Controversial reports are available regarding the status of magnesium on glycemic control in type 2 diabetes mellitus. Serum magnesium levels are not investigated in routine practice despite its significance. Aims: The present study was designed to compare the serum magnesium of type 2 diabetic patients without complications with those of non diabetic controls and to assess the relationship between these two. Setting and Design: Prospective cross sectional study in rural setting of Haryana. Materials and Methods: 50 healthy controls and 100 patients with type 2 diabetes mellitus without complications were recruited from Medicine OPD of MMIMSR, Mullana, Ambala (Haryana), and their serum glucose and serum magnesium levels were measured and compared. Statistical Analysis: By SPSS version 12 [SPSS v12 (SPSS Inc., Chicago, IL)]. Results: The serum magnesium levels were significantly lower in diabetic subjects. Conclusions: Serum magnesium status needs to be routinely checked in diabetic patients and, if reduced, need to be appropriately corrected.
Keywords: Complications; diabetes mellitus; glucose; magnesium.
REFERENCES
1.Parizadeh SM, Faal G, Valaee L. Maternal serum magnesium level and low birth Weight neonate. Int J Prev Med 2013; 4(12): 1476–79.
2.Zimet P, Albert KG, Shaw J. Global and societal implications of diabetes epidemic. Nature 2001; 414: 782-87.
3.Nair P, Christensen MS, Christensen C, Masbad S, Transbol I. Renal hypomagnesemia in human diabetes mellitus: its relation to glucose homeostasis. Eur J Clin Invest 1982; 12; 81-5.
4.Geiger H, Wanner C. Magnesium in disease. Clin Kidney J 2012; 5(1) 26-38.
5.Pham PC, Pham PM, Pham SV, Miller JM, Pham PT. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366–73.
6.Dayanand CD, Krishamurthy N, Kiran S, Naveen. Evaluation of biochemical parameters evincing atherogenic potency in type 2 diabetic retinopathy. Int J Biol Med Res 2011; 2 (2):539-42.
7.Hans CP, Sialy R, Bansal DD. Magnesium deficiency and diabetes mellitus. Curr Sci 2002;83(12): 1456-63.
8.Paolisso G, Barbagallo M. Hypertension, diabetes mellitus and insulin resistance. The role of intracellular magnesium. Am J Hypertens 1997; 10 (3): 346-55.
9.Powers CA. Diabetes mellitus. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo BL,Jameson JL, editors. Harrison’s principles of internal medicine, 17th edition. United States of America (New York): Mc Graw Hill Company, Inc; 2008, p. 2275-2304.
10.Basak A. Development of a rapid and inexpensive plasma glucose estimation by two point kinetics method based on glucose–oxidase-peroxidase enzymes. Indian J Clin Biochem 2007; 22(1): 156-60.
11.Barbour HM, Davidson W. Studies on measurement of plasma magnesium: application of magnon dye method to the “monarch” centrifugal analyzer. Clin Chem 1988; 34: 2103-5.
12.Cockram C, Chan J. The epidemiology of diabetes in the Western Pacific Region (excluding Japan). In: Turle J, Kaneko T, Osato S, Eds. Diabetes in the New Millennium. Sydney, Pot Still Press, 1999, p. 11–22.
13.Wilson WF, Anderson M, Kannel B. Epidemiology of diabetes mellitus in the elderly the Framingham study. Am J Med 1986; 80(5): 3-9.
14.Nakagami T, Qiao Q, Tuomilehto J, Ballau B, Cartensen B, Tajima N, et al. The fasting plasma glucose cut-point predicting a diabetic 2hr OGTT glucose level depends on the phenotype.Diabetes Res Clin Pract 2002; 55: 35-43.
15.Mane M, Chaudhary RG, Reddy PE. Hypomagnesemia in diabetic patient and biochemical action on cardiovascular system. Int J Biol Med Res 2012; 3(1): 1273-76.
16.Earle C, Heshka S, Gallagher D, Wang J, Sunyer X, Richard N. Serum magnesium and type 2 diabetes in African Americans and Hispanics: a new cohort study. Am J Clin Nutr 2006;25(6): 509-13.
17.Mooren FC, Kruger K, Volker F, Golf SW, Wadepuhi M, Kraus A. Oral magnesium supplementation reduces insulin resistance in non diabetic subjects- a double blind, placebocontrolled, randomized trial. Diabetes Obes Metab 2011; 13(3):281-4.
Article citation:
Badyal Ashima,Pandey Rajesh,Sodhi KS,Singh Jasbir. Decreased Serum Magnesium in Patients with Uncomplicated Type 2 Diabetes Mellitus. J Pharm Biomed Sci. 2014;04(04):361-364.Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Review article:
N. Lakshmidevi1,*, Khadega Yahyah A. Al-hetar1, G B Kavishankar1,2
Affiliation:-
1Department of Studies in Microbiology, University of Mysore, India
2Department of Studies in Biochemistry, University of Mysore, India
The name of the department(s) and institution(s) to which the work should be attributed:
University of Mysore, India
*To whom it corresponds:-
N. Lakshmidevi
Department of Studies in Microbiology, University of Mysore, India
Ph: +91-0821-2419739+91-0821-2419739
Abstract
Escherichia coli is a commensal bacterium but it can cause different infections for humans and animals after acquisition of virulence factor genes and with the time and by the random usage of antibiotics. It gains resistant to antibiotics that can be transmitted by E. coli to other pathogenic bacteria. Many measures and investigations should to be taken as a kind of prevention and to reduce the damages that will be caused by E. coli.
Keywords: E. coli, ESBLs, Phylogenetic Groups, Resistance Genes, Virulence Factors.
Article citation:
Lakshmidevi N, Al-hetar KY,Kavishankar GB. Extended Spectrum Beta Lactamase Producing Extraintestinal Pathogenic Escherichia coli (ESBL-ExPEC). J Pharm Biomed Sci 2014;04(04):343-355. Available at www.jpbms.info.
REFERENCES
1.Al-Jasser AM. Extended-Spectrum Beta-Lactamases (ESBLs): A Global Problem. J Kuwait Med Assoc 38. 2006;3:171-185.
2.Alobwede I, M'Zali FH, Livermore DM, Heritage J, Todd N, Hawkey P M,. CTX-M extended-spectrum β-lactamase arrives in the UK. J. Antimic.l Chemo. 2003;51: 470-471.
3.Arisoy M, Rad AY, Akan A, Akar N. Relationship between susceptibility to antimicrobials and virulence factors in pediatric Escherichia coli isolates. Int J Antimic Agen. 2008;31: 4-8.
4.Atifah MN, Loo H, Subramaniam G, Wong E, Selvi P, Ho S, Kamarulzaman A, Parasakthi N,. Faecal prevalence of extended-spectrum β-lactamase (ESBL)-producing coliforms in a geriatric population and among haematology patients. Malays J Pathol. 2005;27(2):75-81.
5.Baldy-Chudzik K, Mackiewicz P, Stosik M. Phylogenetic background, virulence gene profiles, and genomic diversity in commensal Escherichia coli isolated from ten mammal species living in one zoo. Vetmic.2008;3977.
6.Bekal S, Brousseau R, Masson K, Prefontaine G, Fairbrother J, Harel J,. Rapid Identification of Escherichia coli Pathotypes by Virulence Gene Detection with DNA Microarrays. J Clin Micro. 2003;41(5):2113–2125.
7.Blanco1 M, Alonso M, Nicolas-Chanoine M, Dahbi G, Mora A, Blanco, J, Lo´pez1 C, Corte´s P, Llagostera, M. Molecular epidemiology of Escherichia coli producing extended-spectrum b-lactamases in Lugo (Spain): dissemination of clone O25b:H4-ST131 producing CTX-M-15. J Anti Chemo. 2009;63:1135–1141.
8.Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Anti Agen &Chemo.2004;48(1):1-14.
9.Bradford PA, Yang Y, Sahm D, Grope I, Gardovska D, Storch G. CTX-M-5, a novel cefotaxime-hydrolyzing β-lactamase from an outbreak of Salmonella typhimurium in Latvia. Antimic. Agen. & Chemo. 1998;42(8):1980-1984.
10.Branger C, Zamfir O, Geoffroy S, Laurans G, Arlet G, Thien HV, Gouriou S, Piacard B, Denamur E. Genetic background of Escherichia coli and extended-spectrum β- lactamase type. Eme Infec Dise. 2005;11(1):54-61.
11.Carlos C, Pires M, Stoppe N, Hachich E, Sato M, Gomes T, Amaral L, Ottoboni L. Escherichia coli phylogenetic group determination and its application in the identification of the major animal source of fecal contamination. Bio Cent Micro. 2010; 10:161.
12.Chapman TA, Wu X, Barchia I, Bettelheim K, Driesen S, Trott D, Wilson M, Chin J. Comparison of virulence gene profiles of Escherichia coli strains isolated from healthy and diarrheic swine. Appli & Envir Micro.2006;72 (7):4782–4795.
13.Chmelnitsky I, Carmeli Y, Leavitt A, Schwaber MJ, Venezia SN. CTX-M-2 and a new CTX-M-39 enzyme are the major extended in spectrum beta-lactamases multiple Escherichia coli clones isolated in Tel Aviv, Israel. Anti Agen &Chemo. 2005;49 (11): 4745-4750. 14. Chroma M, Kolar M. Genetic Methods For Detection of Antibiotic Resistance: Focus on Extended-Spectrum β-Lactamases. Biomed Pap. Med. Fac. Univ. Palaky Olomouc Czech Repup. 2010, 145(4):289-296.
15.Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic groups. Appli & Envir Micro. 2000; 66 (10):4555-4558.
16.Clermont O, Johnson J, Menard M, Denamur E. Determination of Escherichia coli O types by allele-specific polymerase chain reaction: application to the O types involved in human septicemia. Diag Micr & Infec Dis.2007;57:129–136.
17.Dutour C, Bonnet R, Marchandin H, Boyer M, Chanal C, Sirot D, Sirot J,. CTX-M-1, CTX-M-3, and CTX-M-14 β- lactamases from Enterobacteriaceae isolated in France. Antimic Agen & Chemo. 2001;46 (2):534-537.
18.Eckeret C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, Barnaud G, Delisle F, Rossier A, Lambert T, Philippon A, Alert G,. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Anti Agen & Chemo. 2004; 48(4):1249-1255.
19.Eisner A, Fagan E J, Feierl G, Kessler H H, Marth E, Livermore DM, Woodford N. Emergence of enterobacteriaceae isolated producing CTX-M extended-spectrum β-lactamase in Austria. Antimi. Agen. Chemo. 2006;50(2):785-787.
20.Emody L, Pál T, Hacker J, Blum-Oehler G. Genes and proteins underlying microbial urinary tract virulence basic aspects and applications. New York. Kluw Acade Publis. 2002.
21.Escobar-Páramo P, Menac’h A, Gall T, Amorin A, Gouriou S, Picard B, Skurnik D, Denamur E. Identification of forces shaping the commensal Escherichia coli genetic structure by comparing animal and human isolates. Enviro Microb.2006; 8(11):1975–1984.
22.Gordon D, Cowling A. The distribution and genetic structure of Escherichia coli in Australian vertebrates: host and geographic effects. Microb. 2003;149:3575–3586.
23.Guibout VL, Jurand C, Bonacorsi S, Espinasse F, Guelfi MC, Duprotail F, Heym B, Bingen E, Chanoine MHN. Emergence and spread of three clonally related virulent isolated of CTX-M-15-producing Escherichia coli with variable resistance to aminoglycosdes and tetracycline in a France geriatric hospital. Anti Agen & Chemo. 2004;48(10): 3736-3742.
24.Hamelin K, Bruant G, El-Shaarawi A, Hill S, Edge TA, Fairbrother J., harel J, Maynard C, Masson L, Brousseau R. Occurrence of virulence and antimicrobial resistance genes in Escherichia coli isolates from different aquatic ecosystems within the St. Clair River and Detroit river areas. Appli & Enviro Micro. 2006;73(2):477-484.
25.Highland M, Byrne B, DebRoy C, Samitz E, Peterson T, Oslund K. Extraintestinal pathogenic Escherichia coli induced pneumonia in three kittens and fecal prevalence in a clinically healthy cohort population. J Veteri Diagno Invest.2009;21:609.
26.Ho PL, Wong RC, Chow KH, Yip K, Wong SS, Que TL. CTX-M type beta-lactamases among fecal Escherichia coli and Klebsiella pneumoniae isolates in non- hospitalized children and adults. J Micro Immun & Infect.2008;41:428-432.
27.Hoek AH A, Mevius D, Guerra B, Mullany P, Roberts AP, Aarts HJM. Acquired antibiotic resistance genes: an overview. Front. in Microb. 2011;2(203):1-27.
28.Hudault S, Spiller B, Morgan P, Servin A. Human diffusely adhering Escherichia coli expressing afa/dr adhesins that use human CD55 (Decay-Accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55. Infect & Immu. 2004;72(8): 4859–4863.
29.Hull R, Bieler S, Falkow S, Hull S. Chromosomal map position of genes encoding P adhesins in uropathogenic Escherichia coli. Infect & Immun. 1985;51(2):693-695.
30.Jaureguy F, Landraud L, Passet V, Diancourt L, Frapy E, Guigon G, Carbonnelle, E, Lortholary, O, Clermont, O, Denamur, E, Picard, B, Nassif, X, Brisse, S. Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. BioM Cent Geno. 2008;9(560):1-14.
31.Jayaraman R. Antibiotic resistance: an overview of mechanisms and a paradigm shift. Curr Sci India. 2009;96:1475–1484.
32.Jeong SH, Bae IK, Kwon SB, Lee JH, Song JS, Jung HI, Sung KH, Jang SJ, Lee SH. Dissemination of transeferable CTX-M-type extended- spectrum β-Lactamase- producing Escherichia coli in Korea. J Appli Microb.2005;98:921-927.
33.Johnson J, Russo T, Tarr P, Carlino U, B. Svary J, Stell A. Molecular epidemiological and phylogenetic associations of two novel putative virulence genes, iha and iroN E. coli, among Escherichia coli isolates from patients with urosepsis. Infect & Immun.2000; 68(5):3040–3047.
34.Johnson J, Delavari P, Kuskowski M, Stell A. Phylogenetic distribution of extra intestinal virulence-associated traits in Escherichia coli. J Infect Dise. 2001;183:78–88.
35.Johnson JR, Kuskowski MA, Owens K, Gajewski A, Winokur PL. Phylogenetic origin and virulence genotype in relation to resistance to flouroquinolones and/or extended-spectrum cephalosporins and cephamycins among Escherichia coli isolates from animals and humans. J Infec Dise.2003;188:759-768.
36.Johnson J, Jelacic S, Schoening L, Clabots C, Shaikh N, Mobley H, Tarr P. The irgA homologue adhesin iha is an Escherichia coli virulence factor in murine urinary tract tnfection. Infect & Immu.2004;73(2):965–971.
37.Johnson JR, Kuskowski MA, O’Bryan TT, Colodner R, Raz R. Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis. Anti Agen & Chemo.2005; 49(1):26-31.
38.Johnson J, Owens K, Clabots C, Weissman S, Cannon S. Phylogenetic relationships among clonal groups of extraintestinal pathogenic Escherichia coli as assessed by multi-locus sequence analysis. Micro & Infect. 2006;8:1702-1713.
39.Johnson JR, Menard M, Johnston B, Kuskowski MA., Nichol K, Zhanel G G. Epidemic clonal groups of Escherichia coli as a cause of antimicrobial-resistant urinary tract infections in Canada, 2002 to 2004. Antim. Agen Chemo. 2009;53:2733–2739.
40.Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence typeST131as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin. Infect. Dis. 2010;51:286–294.
41.Karisik E, Ellington MJ, Livermore DM, Woodford N. Virulence factors in Escherichia coli with CTX-M-15 and other extended spectrum β-lactamases in the UK. J Anti Chemo.2007;61: 54-58.
42.Kere´nyi M, Allison H, Ba´tai I, Sonnevend A, Emo¨dy L, Plaveczky N, Pa´l1 T. Occurrence of hlyA and sheA genes in extraintestinal Escherichia coli strains. J Clin Micro. 2005;43(6):2965–2968.
43.Kiratisin P, Apisarnthanark A, Laesripa C, Saifon P. Molecular characterization and epidemiology of extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumonia isolated causing health care-associated infection in Thailand, where the CTX-M family is endemic. Anti Agen & Chemo. 2008; 52(8): 2818-2824.
44.Knothe H, Shah P, Krcmery V, Antal M, Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumonia and Serratiamarcescens. J Infec. 1983; 11: 315-317.
45.Kuntaman K, Lestari ES, Severin JA, Kershof IM, Mertaniasih NM, Purwanta, M., Hadi, U, Johnson JR, Belkum A, Verbrugh HA. Fluoroquinolone-resistant Escherichia coli, Indonesia. Emer Infect Dis. 2005;11 (9):1663-1669.
46.Lambert PA. Bacterial resistance to antibiotics: modified target sites. Adv Drug Deliv Rev.2005;57: 1471–1485.
47.Lavigne JP, Marchandin H, Delmas J, Moreau J, Bouziges N, Lecaillon E, Cavalie L, Pierre HJ, Bonnet R, Sottoo A. CTX-M β-lactamase-producing Escherichia coli in French hospitals: prevalence, molecular epidemiology, and risk factors. J Clin Micro. 2006;45(2):620-626.
48.Lavigne JP, Blanc–Potard AB, Bourg G, Moreau J, Chanal C, Bouziges N, Callaghan DO, Sotto A. Virulence genotype and nematode-killing properties of extra-intestinal Escherichia coli producing CTX-M β-lactamases. J Clin Micro & Infec Dis. 2006;12(12): 1199-1206.
49.Lecointre G, Rachdi L, Darlu P, Denamur E. Escherichia coli Molecular phylogeny using the incongruence length difference test. The Soci for Molec Bio & Evol. 1998; 15(12): 1685–1695.
50.LewisII JS, Herrera M, Wicker B, Patterson JE, Paterson JH. First report of the emergence of the CTX-M-type extended-spectrum β-lactamase (ESBLs) as the predominant ESBL isolated in a U.S. health care system. Anti Agen & Chemo. 2007; 51(11): 4015-4021.
51.Machado E, Canton R, Baquero F, Galan JC, Rollan A, Peixe L, Coque TM. Integron content of extended-spectrum-β-lactamase-producing Escherichia coli strains over 12 years in a single hospital in Madrid, Spain. Anti Agen & Chemo. 2005; 49 (5): 1823-1829.
52.Mamlouk K, Boubaker IB, Gautier V, Vimont S, Picard B, Redjeb SB, Arlet G. Emergence and outbreak of CTX-M β-lactamase-producing Escherichia coli and Klebsiella pneumonia strains in a Tunsian hospital. J Clin Micro. 2006; 44 (11): 4049- 4056.
53.MainousIII AG, Pomeroy C. Management of antimicrobials in infectious diseases. Totowa, New Jersey: Humana Press. 2001.
54.Manges A, Tabor H, Tellis P, Vincent C, Tellier P. Endemic and epidemic lineages of Escherichia coli that cause urinary tract infections. Emer Infec Dis. 2008; 14 (10): 1575-1583.
55.Manning SD. Deadly diseases and epidemics Escherichia coli infections. USA: Chelsea House Publishers. 2004.
56.Martinez LM, Fernnandez F, Perea EJ. Relationship between Haemolysis production and resistance to fluoroqunolones among clinical isolates of Escherichia coli. J Anti Chemo. 1999; 43: 277-279.
57.McCraken M. Characterization of extended-spectrum beta-lactamases (ESBLs) in North America. University of Manitoba, Canada, 2006.
58.Meier C, Oelschlaeger TA, Merkert H, Korhonen TK, Hacker JR. Ability of Escherichia coli isolates that cause meningitis in newborns to invade epithelial and endothelial cells. J Infec & Immun. 1996; 64 (7): 2391-2399.
59.Mendonca N, Leitoe J, Manageiro V, Ferreira E, Canica M. Spread of extended-spectrum β-lactamase CTX-M-producing Escherichia coli clinical isolates in community and nosocomial environments in Portugal. Anti. Agen & Chemo. 2007; 51(6): 1946-1955.
60.Mora A, López C, Dabhi G, Blanco M, Blanco J, Alonso M, Herrera A, Mamani R, Bonacorsi S, Moulin-Schouleur M, Blanco J. Extra intestinal pathogenic Escherichia coli O1:K1:H7/NM from human and avian origin: detection of clonal groups B2 ST95 and DST59 with different host distribution. BioM Cent Micro. 2009; 9(132).
61.Moreno JE, Planells I, Prats G, Planes AM, Moreno G, Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing urinary tract bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diag Micro & Infect Dis. 2005; 53: 93-99.
62.Nazareth H, Genagon SA, Russo T. Extraintestinal pathogenic Escherichia coli survives within neutrophils. Infec & Immun. 2007; 75 (6): 2776–2785.
63.Nicolle L, Association of Medical Microbiology and Infectious Diseases (AMMI) Canada Guidelines Committee.. Complicated urinary tract infection in adults. The Can J of Infect Dis & Med Micro. 2005; 16 (6): 349-360.
64.Nowicki B, Selvarangan R, Nowicki S. Family of Escherichia coli dr adhesins: decay-accelerating factor receptor recognition and invasiveness. J Infec Dis. 2001; 183 (1): 24-27.
65.Nowrouzian F, Adlerberth I, Wold A. Enhanced persistence in the colonic microbiota of Escherichia coli strains belonging to phylogenetic group B2: role of virulence factors and adherence to colonic cells. Micro& Infect. 2006; (8):834-840.
66.Obata-Yasuoka M, Ba-Thein W, Tsukamoto T, Yoshikawa H, Hayashi H, Vaginal Escherichia coli share common virulence factor profiles, serotypes and phylogeny with other extra intestinal E. coli. J Microb. 2002; 148: 2745–2752.
67.Oelschlaeger TA, Dobrindt U, Hacker J. Pathogenicity islans of uropathogenic E. coli and the evolution of virulence. Inter J Anti Agen. 2002; 19: 517-521.
68.Pagani L, Amico ED, Migliavacca R, D’Andrea MM, Giacobone E. Amicosante G, Romero E, Rossolini GM. Multiple CTX-M-type extended spectrum β-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in Northen Italy. J Clin Micro. 2003; 41(9): 4264-42-69.
69.Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microb Rev. 2005; 18(4): 657-686.
70.Peirrano G, vanderBij AK, Greg- son DB, Pitout JD. Molecular epidemiology over an eleven-year period (2000-10) of extended-spectrum beta-lactamase- producing Escherichia coli causing bacteraemia in a centralized Canadian region. J. Clin .Microbiol. doi. 2011; 50(2):294-299.
71.Piatti G, Mannini A, Balistreri M, Schito AM. Virulence factors in urinary Escherichia coli strains: Phylogentic background and quinolone and flouroquinolone resistance. J Clin Microb. 2007;46 (2):480-487.
72.Picard B, Garcia JS, Gouriou S, Duriez P, Brahimi N, Bengen D, Elion J, Denamur E. The link between phylogeny and virulence in Escherichia coli extra intestinal infection. J Infec & Immun. 1998;67(2): 546-553.
73.Pitout JDD, Laupland KB, Church DL, Menard ML, Johnson JR. Virulence factors of Escherichia coli isolates that produce CTX-M type extended-spectrum β-lactamases. Anti Agen & Chemo. 2005; 49(11):4667-4670.
74.Pitout JDD, Laupland KB. Extended spectrum beta-lactamases producing Enterobacteriaceae: an emerging public health concern. Lancet. Infect. Dis. 2008; 8:159-166.
75.Pitout JD, Gregson, DB, Camp-bell L, Laupland KB. Molecular characteristics of extended-spectrum-beta-lactamase-producing Escherichia coli isolates causing bacteremia in the Calgary Health Region from 2000 to2007: emergenceofclone ST131 as a cause of community-acquired infections. Anti. Agen Chemo. 2009; 53:2846–2851.
76.Pitout JD. Extra-intestinal pathogenic Escherichia coli: a combination of virulence with antibiotic resistance. Anti Agen & Chemo. 2012; 3(9): 1-7
77.Poirel L, Kampfer P, Nordamann P. Chromosome encoded ambler class A β-lactamases of Kluyvera Georgiana, a probable progenitor of a subgroup of CTX-M extended-spectrum β-lactamases. Anti Agen & Chemo. 2002;46(12) 4038-4040.
78.Prelog M, Fille M, Prodinger W, Grif K, Brunner A, Würzner R, Zimmerhackl LB. CTX-M-1-Related Extended-Spectrum Beta-Lactamases Producing Escherichia coli: so far a Sporadic Event in Western Austria. J. of Infect. 2008;36 (4):362-367.
79.Queener SF, Webber JA, Queener SW. Beta-lactam antibiotics for clinical use. New York. Marcel Dekker. 1986.
80.Rasheed JK, Jay C, Metchock B, Berkowitz F, Weigel L, Crellin J, Steward C, Hill B, Medeiros AA, Tenover FC. Evolution of extended spectrum β- lactam resistance (SHV-8) in a strain of Escherichia coli during multiple episodes of bacteremia. Anti Agen & Chemo. 1997;41(3):646-653.
81.Rogers BA, Sidjabat HEm, Patreson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J. Anti. Chemo. 2011; 66:1-14.
82.Russo T, Carlino U, Mong A, Jodush S. Identification of genes in an extraintestinal isolate of Escherichia coli with increased expression after exposure to human urine. Infect & Immun. 1999; 67(10): 5306.
83.Russo TA, Johnson JR,. Medical and economic impact of extra-intestinal Infections Due to Escherichia coli: focus on an increasingly important endemic problem. J Mic.& infect. 2003; 5: 449-456.
84.Ryan KJ, Ray CG. Sherris medical microbiology: An introduction to infectious diseases. USA. The McGraw-Hill Companies.2004.
85.Ryoo NH, Kim E, Hong SG, Park YJ, Lee K, Bae IK, Song EH, Jeong SH. Dissemination of SHV-12 and CTX- M-type extended-spectrum β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae and emergence of GES-3 in Korea. J Anti Chemo. 2005;56:698-702.
86.Sabate M, Prats G, Moreno E, Balleste E, Blanch AR, Andreu A. Virulence and antimicrobial resistance profiles among Escherichia coli strains isolated from human and animal wastewater. Res Microb. 2008;159:288-293.
87.Schouleur MM, Reperant M, Laurent S, Laurent S, Bree A. Extra-intestinal pathogeneic Escherichia coli strains of avian and human origin: link between phylogenetic relationships and common virulence patterns. J Clin Microb. 2007;45(10):3366-3376.
88.Schwertmann A, Schroten H, Hacker J, Kunz C. S-fimbriae from Escherichia coli bind to soluble glycoproteins from human milk. J Ped Gastr & Nutr. 1999;28(3):257-63.
89.Servin AL. Pathogenesis of afa/dr diffusely adhering Escherichia coli. clin Microb Rev. 2005; 18 (2):264–292.
90.Sharma S, Bhat G, Shenoy S. Virulence factors and drug resistance in Escherichia coli isolated from Extra-intestinal infections. Indi J Med Microb. 2007; 25 (4):369-373.
91.Siu LK, Lu PL, Hsueh PR, Lin MF, Chang SC, Luh KT, Ho M, Lee CY,. Bacteremia due to extended- spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a pediatric oncology ward: clinical features and identification of different plasmids carrying both SHV-5 and TEM-1 genes. J Clin Microb. 1999;37(12):4020-4027.
92.Subramaian G, Palasubramanian S, Navartanam P. SHV-5 extended spectrum β-lactamases in clinical isolates of Escherichia coli in Malaysia. Indi J Med Microb. 2006;24(3):205-207.
93.Talaro KP, Talaro A. Foundations in microbiology: Basic principles. New York. McGraw-Hill, 2002
94.Tarr P, Bilge S, Vary J, Jelacic S, Habeeb H, Ward T, Baylor M, Besser T. Iha: a novel Escherichia coli O157:H7 adherence-conferring molecule encoded on a recently acquired chromosomal island of conserved structure. Infect Immun. 1999;68(3): 1400-1407.
95.Todar, K., 2008. Pathogenic E. coli. U.S.A. (www.textbookofbacteriology.net).
96.Tofteland E, Haldorson B, Dahl KH, Simonsen GS, Steinbakk M, Walsh TR, Sundsfjord A, The Norwegian ESBL study group. Effect of phenotype and genotype on methods for detection of extended-spectrum-β-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microb. 2006;45(1): 199-205.
97.Vimont S, Aubert D, Mazoit JX, Poirel L, Nordman P. Broad spectrumβ Lactams for treating experimental peritonitis in mice due to Escherichia coli Producing plasmid-encoded cephalosporinases. J Anti Chemo. 2007;60:1045-1050.
98.Wiles T, Kulesus R, Mulvey M,.Origins and virulence mechanisms of uropathogenic Escherichia coli. Exper. & Molec. Patho. 2008;85(1):9-11.
99.Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, Johnson AP, Pike R, Warner M, Cheasty T, Pearson A, Harry S, leach JB, Loughrey A, Lowes JA, Warren RE, Livermore DM. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum β-lactamases in the UK. J Antimic. Chemo. 2004;54:735-743.
100.Yu Y, Ji S, Chen,Y, Zhou W, Wei Z, Li L, Ma Y. Resistance of strain producing extended-spectrum β-lactamases and genotype. J Infec. 2007; 54:53-57.
101.Zhang L, Foxman B, Marrs C. Both urinary and rectal Escherichia coli isolates are dominated by strains of phylogenetic group B2. J Clin Microb, 2002; 40(11):3951–3955.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Lakshmidevi N, Al-hetar KY,Kavishankar GB. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Research article:
Idoko J1,*, Enemari JO1, Okolo SC1, Yaro DJ1, Akpulu, P2, Mairiga AA1, Aghenumu L1, Owolagba G1, Dasi KR3,Anyebe EE4 , Ameh EA5, Ogboi SJ3
Affiliation:-
1Department of Pathology Ahmadu Bello University Teaching Hospital Zaria
2Department of Human Anatomy Ahmadu Bello University Zaria
3Research and Training Unit, Department of Nurse Education, ABU Teaching Hospital Zaria.
4Paediatric Surgery Unit, Department of Surgery, A.B.U. Teaching Hospital Zaria, Nigeria
5Public Health Lab. Department of Med. comm. ABU Zaria
The name of the department(s) and institution(s) to which the work should be attributed:
1.Department of Pathology Ahmadu Bello University Teaching Hospital Zaria.
2.Department of Human Anatomy Ahmadu Bello University Zaria.
3.Research and Training Unit, Department of Nurse Education, ABU Teaching Hospital Zaria.
4.Paediatric Surgery Unit, Department of Surgery, A.B.U. Teaching Hospital Zaria, Nigeria
5.Public Health Lab. Dept of Med. comm. ABU Zaria.
*To whom it corresponds:-
Idoko J.
Department of Pathology Ahmadu Bello University Teaching Hospital Zaria.
Contact number:- +2348061397320+2348061397320
Abstract:
High incidence of death has been associated with cervical cancer in the developing countries in the recent times, and so it is imperative to advance its detection. Hairspray (NOVA) was compared with routine 95% ethanol to assess the efficiency in cyto diagnosis of cervical smear. Two hundred (200) cervical smeared samples in duplicate were collected from patients, carefully labeled and were fixed immediately, using routine 95% ethanol and with hairspray (Nova) respectively. The slides were stained by papanicolaou technique and were evaluated. There was no degeneration of cell morphology and no significant toxic effect of the Hairspray (NOVA) when compared with 95% alcohol. The cells appeared normal, without shrinkage and with a clear background and good nuclear outline. Hairspray (NOVA) is cost effective, efficient, handy and easy to use. It is shown that, hairspray (Nova) is effective for cervical smear.
Keywords: Hairspray; routine fixative; cervical smear.
REFERENCES
1.Baharom Anisah, Ismail Maimunah. Case Studies on Decision for Cervical Cancer Screening among Working Women The Journal of Human Resource and Adult Learning,2008:4(2):173-183.
2.Bancroft J D and Stevens (2010) Theory and Practice of Histopathological Techniques 3rd ed P 466. Churchhill Livingstone London, New York.
3.Freeman, J. A. (1969): Fixation of smears using cytofixative Acta Cytol.(philad.),13,416.
4.Innovatek Medical Inc. ( 2003) #3- 1600 Derwent way, Delta Canada. V3MS6M5.
5.Kumar, Vinar; Abbas, Abul k, Fausto, Nelson; Mitchell, Richard N. (2007). Robbins Basic Pathology (8th ed.) sauders Elsevier. London.
6.Kumarasinghe M P, Constantine T S R, Hemarnali T R LC. Methanol as an alternative fixative for cytological smears, Malaysian J Patlzol,1997;19(2): 137 – 140.
7.Lim G.C.C. Halimah Y. (2004) Second Report of the National Cancer Registry. Cancer Incidence in Malaysia 2003. National Cancer Registrt. Kuala Lumpur.
8.Markovic, M., Kesic V., Topic L., Matejic, B. Barriers to cervical cancer screening: a qualitative study with women in Serbia. Social science and medicine,2005; 61:2528-2535.
9.Ramzi SC Stanley RL, Vinary K (1999) Disease of The Female Genital Tract in pathologic basis of disease 6th ed. Published by Saunders philadephia London Toronto Mexico city.
10.Shamsi M, Abdali K, Montazer NR, Kumar PV, Tabatabaee HR. Comparison of Carnoy's solution and 96% ethyl alcohol fixation in bloody Pap smears.Acta Cytol. 2003;47(4):630-6.
11.Utian, Wulf H. Hairspray as an Inexpensive Fixative for Papanicolaou Smears South Africa medical journal , 1972;46 835-837.
Article citation:
Idoko J, Enemari JO, Okolo SC, Yaro DJ, Akpulu P, Mairiga AA et al. Hairspray (NOVA) as a substitute for Routine fixatives in cervical smear. J Pharm Biomed Sci 2014; 04(04): 327-331. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Idoko J, Enemari JO, Okolo SC, Yaro DJ, Akpulu P, Mairiga AA et al. . This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article.
B. N. Pandey1,*,D. Kumar1, Esha2
Affiliation:-
1Eco-genetical Research Laboratory, P.G. Department of Zoology, 2P.G.Department of Economics Purnea College Purnia, Bihar,India.
The name of the department(s) and institution(s) to which the work should be attributed:
P.G. Department of Zoology, P.G .Department of Economics Purnea College Purnia, Bihar, India.
*To whom it corresponds:-
B. N. PANDEY.
P.G. Department of Zoology, Purnia College Purnia, Bihar, India
Abstract
Terai belt of Bihar is an agricultural zone. Economically it is a backward zone. The economy is agriculture dependent. About 70% women of weaker sections work as daily laborers in agricultural fields, 10% in brick factories and remaining as maid servants or in Angan Badi. The health status of these rural women of Terai belt was studied in relation to housing type, sanitation and occupation. The general health of rural women of Terai belt is not satisfactory. They are victim of a large number of diseases such as anemia, menstrual disorders, leucorrhea, arthritis, asthma, skin diseases, TB, malaria, filarial, kala-azar etc. The main reasons behind their health are poor and insanitary houses, poor socio-economic condition, poor literacy, poor facility of drinking water and their occupation. It is the need of time that these rural women should be provided better health care facilities for their better future. There must be regular environmental awareness programmes at village level. To educate them about sanitation, personal hygiene and protection against their work related aspects should be first step towards better of their health. They must be convinced about the bad effect of insanitary condition, ill ventilated house, disposal of garbage near houses, drinking of contaminated water as well as taking food without proper cleaning of hands. All these can be done with the help of slides, posters and films etc.
Keywords:Health status; rural women; terai belt; sanitation; personal hygiene.
REFERENCES
1.Thaiyalnaayki T. (2010). Importance of women health from economic prospective. www. Articlebase.com (12 May).
2.Menon AGG and Prema LC. Retention of knowledge of human nutrition by rural women as related to their socio-economic status. Ind. J. Home Sc. 1978;12: 107 – 110.
3.Bhatt CM and Kheterpal M. Infant feeding practices in selected villages of Hissar district. Ind. J. Nut. Dietit. 1983; 23: 1 – 2.
4.Mohapatra SS. (1984). Rural perinatal mortality. Ind. J. Peditatrics.1984;21: 645 – 649.
5.Mir NA (1986). Regionalizatin of perinatal mortality. Ind. J. Peditatrics.1986;3:335–338.
6.Basu, S. K. (1993). Health status of Tribal women in India. Status paper for the National Workshop on “Status of Tribal Women in India” organised by Council for Social Development, New Delhi.
7.Patil AV, Somasundaram KV and Goyal RC. Current health scenario in rural India. Aust. J. Rural Health. 2002;10:129 – 135.
8.Pandey, BN, Jha AK ,Das PKL and Ojha AK. Socio-ecological aspects of tribes of Koshi zone in relation to health. Contemporary Studies in Human Ecology, Kamla Raj Prakashan. 1998; Delhi, 339 – 348.
9.Pandey, BN, Das PKL, Jha AK and Ojha AK. (2002). Foetal wastage, infant mortality and ecological and social factors in six tribal groups of Jharkhand. In: Eco-degradation, Bio-diversity and Health. Pandey BN (Ed). Daya Publishing House, Delhi.
10.Pandey BN, Vatsa S and Ambasta OP. Foetal wastage and infant mortality in two tribal populations of Jharkhand. Man in india. 2005;85 (3 & 4): 255 – 263.
11.Mohindra KS, Haddad S and Narayana D. Women’s health in rural community in Kerala, India: do caste and socioeconomic position matter? J Epidemiol Community Health. 2006; 60(12): 1020–1026.
12.Saha UC, Saha KB. A trend in women’s health in India – what has been achieved and what can be done. Rural and Remote Health 10: 1260. (Online) 2010. Available: http://www.rrh.org.au
13.Vandana K. The health status of women of India. Res. J. Chem. & Env. Sci. 2013;1(3):66-69. Available Online http://www.aelsindia.com
14.Indian Policy through a non-partisan prism (2013), Jan., 26.
15.APHA (1989); Standard methods for the examination of water and waste water. 17th edition, Washington, U.S.A.
16.Trivedy, R.K., and Goel, P.K. (1984): Chemical and Biological methods for Water Pollution Studies Env. Pub. Karad India.
17.Dhanalakshmi, N. and Murthy, M. S. R. Environmental correlates of child morbidity in Andhra Pradesh. J. Fam. Welf. 1993;3(30):18 – 27.
18.India's Rural Poor-Knowledge@Wharton - University of Pennsylvania. (2007). knowledge.wharton.upenn.edu/.../indias-rural-poor-why-housing-isnt-en.
19.Upadhyayula SM, Mutheneni SR, Kadiri MR, Kumaraswamy S, Nagalla B. A Cohort Study of Lymphatic Filariasis on Socio Economic Conditions in Andhra Pradesh, India. PLoS ONE. 2012; 7(3): e33779. doi:10.1371/journal.pone.0033779
20.Pandey BN, Kumar D and Verma DK. Epidemiological study of parasitic infestations in rural women of Terai belt of Bihar, India. Ann. Biol. Res.2013; 4(11):30–33.
21.EIU, (1997). India Nepal: Country Profile, The Economist Intelligence Unit, London.
22.Gupta S, Sharma ML and Darshan S. Health problems and promotive programmes in rural community - A case study in Haryana. HAU Journal of Research. 1981; 11: 1, p. 93-99.
23.Ray SK. Prevalence of dental fluorosis in relation to fluoride in drinking water in two villages of Varanasi (UP.). Indian Journal of Public Health. 1982;26:3,p.173-178.
24.Indian women above 40 are more prone to arthritis. (2009).The Hindu, Oct., 13.
25.Scott, DL; Wolfe, F; Huizinga, TW. "Rheumatoid arthritis". Lancet (2010 Sep 25);376 (9746): 1094–108.
26.Kumar K, Daley E, Carruthers DM et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists’ Rheumatology.2007; 46(9):1438–1440.
27.Band PR, Le ND, Fang R, Deschamps M, Gallagher RP and Yang P. Identification of occupational cancer risks in British Columbia. A population-based case–control study of 995 incident breast cancer cases by menopausal status, controlling for confounding factors. J Occup Environ Med. 2000; 42:284-310.
28.Cohn BA, Wolff MS, Cirillo PM and Sholtz RI. DDT and breast cancer in young women: new data on the significance of age at exposure. Environ Health Perspect.2007; 115:1406-1414.
29.Clapp RW, Jacobs MM and Loechler EL. Environmental and occupational causes of cancer: new evidence 2005–2007.Rev Environ Health. 2008;23:1-37.
30.Brophy JT, Keith MM, Watterson A, Robert Park R, Gilbertson M, Maticka-Tyndale E, Beck M, Abu-Zahra H, Schneider K, Abraham Reinhartz A, Robert Matteo De and Isaac Luginaah I. Breast cancer risk in relation to occupations with exposure to carcinogens and endocrine disruptors: a Canadian case – Control study. Environmental Health. 2012; 11:87. doi:10.1186/1476-069X-11-87.
Article citation:
Pandey BN, Esha DK. Health status of rural women of terai belt of Bihar (India) in relation to housing type, sanitation and occupation. J Pharm Biomed Sci 2014; 04(04):284-290. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Pandey BN, Kumar D,Esha. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Original article:
Abul Fazil MD1, Sheetal Raj M MD2, Aditya Verma MBBS3, Jagadish Rao Padubidri MD, DNB4,*
Affiliation:-
1Assistant Professor, Department of Medicine, 2Senior Resident, Department of Medicine, 3Undergraduate Medical Student,4Associate Professor, Department of Forensic Medicine, Kasturba Medical College, Mangalore,Karnataka, India [Affiliated to Manipal University]
The name of the department(s) and institution(s) to which the work should be attributed:
Department of Medicine, Kasturba Medical College, Mangalore, Karnataka, India [Affiliated to Manipal University].
*To whom it corresponds:-
Dr. Jagadish Rao Padubidri.
Associate Professor, Forensic Medicine and Toxicology, Kasturba Medical College, Light House Hill Road, Mangalore-1, Karnataka, India.[ Affiliated to Manipal University].
Contact No: +91-9900405085+91-9900405085.
Abstract
Background/ objective: Leptospirosis is a spirochetal bacterial infection of great public health importance. Acute pancreatitis is an uncommon gastrointestinal manifestation of leptospirosis. The aims and objective of this study was to find the incidence of hyperamylasemia in cases of severe leptospirosis and to correlate the incidence of hyperamylasemia with acute pancreatitis among patients with severe leptospirosis.
Methods: All patients who were positive for IgM ELISA test (IgM ELISA > 11 panbiounits was considered positive for leptospirosis) and had features suggestive of severe leptospirosis or Weil’s disease were included in the study. Serum amylase levels were assessed in all patients, included in the study. An ultrasound of the abdomen was done to objectively confirm or refute the presence of acute pancreatitis in all patients included in the study.
Results: The study included 25 cases diagnosed of Severe Leptospirosis. 24 out of 25 cases [96 %] had renal failure. All the cases [100%] had deranged liver function tests. 17 out of the 25 [68%] cases had hyperamylasemia. Almost all patients showed evidence of multi organ dysfunction in the form of deranged renal function or hepatic dysfunction or both. Out of the total 25 cases included in the study, 17 cases[68%] showed elevated levels of serum amylase.
Conclusions: It is evident from this study that despite of low reporting, the dangerous complication of acute pancreatitis is not so rare among patients with severe leptospirosis. Hyperamylasemia is commonly seen with an incidence of 68% among these patients. Our study shows that, threefold rise of serum amylase level remains a very specific and cost effective test for detection of acute pancreatitis in patients with severe leptospirosis.
Keywords: Leptospirosis; serum amylase; hyperamylasemia; acute pancreatitis.
REFERENCES
1.Smita B. Shekatkar, Belgode N. Harish, Godfred A. Menezes and Subhash C. Parija. Clinical and serological evaluation of leptospirosis in Puducherry, India . J Infect Dev Ctries. 2010; 4(3):139-143.
2.Susan S Philip, Spirochaetal Infections. In: Stephen J. McPhee, Maxine A Papadakis . editors Current Medical Diagnosis and Treatment 2011.50th edition.The McGraw Hill Companies,Inc;2011. Pg 1414.
3.Ekrem Kaya, Adem Dervisoglu, Cafer Eroglu, Cafer Polat, Mustafa Sunbul, Kayhan Ozkan . Acute pancreatitis caused by leptospirosis: report of two cases . World J Gastroenterol - 2005;11(28):4447-4449.
4.Anne Spichler, Ethel Spichler, Marcelo Moock, Joseph M. Vinetz and John A. D. Leake . Acute pancreatitis in fatal anicteric leptospirosis. Am J Trop Med Hyg. 2007 May;76(5): 886-887.
5.Philip p. Toskes , Norton J. Greenberger . Approach to the patient with pancreatic disease . In:Fauci , Braunwald ,Kasper, Hauser,Longo,Jameson,Loscalzo editors . Harrison’s principles of Internal Medicine. 17th ed .The McGraw Hill Companies ,Inc ; 2008 . pg 2001 -2005.
6.Yadav D, Agarwal N, Pitchumoni C.S. A critical evaluation of laboratory tests in acute pancreatitis.Am J Gastroenterol; 2002 Jun; 97(6):1309-18.
7.Edwards G A, Domm B M. Human leptospirosis. Medicine. 1960;39:117–156.
8.Kelley P. W. Leptospirosis. In: Gorbach S L, Bartlett J G, Blacklow N R, editors. Infectious diseases. 2nd ed. Philadelphia, Pa: W. B. Saunders; 1998. pp. 1580–1587.
9.Turner L H. Leptospirosis I. Trans R Soc Trop Med Hyg. 1967;61:842–855.
10.Paul N. Levett. Leptospirosis. Clinical Microbiology Reviews, Apr. 2001:296–326.
Doi:10.1128/Cmr.14.2.296–326.2001.
11.Heath C. W., Alexander A. D., Galton M. M. Leptospirosis in the United States: 1949–1961. N Engl J Med. 1965; 273:857–864. ,915–922.
12.Abdulkader R. C. R. M. Acute renal failure in leptospirosis. Renal Fail. 1997;.19:191–198.
13.Edwards C. N., Nicholson G. D., Hassell T. A., Everard C. O. R., Callender J. Leptospirosis in Barbados: a clinical study. West Indian Med J. 1990;39:27–34.
14.Ramachandran S., Rajapakse C. N. A., Perera M. V. F., Yoganathan M. Patterns of acute renal failure in leptospirosis. J Trop Med Hyg. 1976;79:158–160.
15.Winearls C. G., Chan L., Coghlan J. D., Ledingham J. G. G., Oliver D. O.. Acute renal failure due to leptospirosis: clinical features and outcome in six cases. Q J Med. 1984; 53:487–495.
16.Farr R.W. Leptospirosis. State-of-the-art article. CID 1995;21: 1-6.
17.Wang N.C., Ni Y.H.,Chanq F.Y. Acute acalculous cholecystitis and pancreatitis in a patient with concomitant leptospirosis and scrub typhus. J Microbiol and Immunol and Infect. 2003; 36(4);285- 287.
18.Brien M.M., Vincent J.M., Person D.A.,Cook B.A., Leptospirosis and Pancreatitis- Report of 10 Cases. J Ped Infect Dis 1998; 17(5); 436-438.
19.Thunga G. , Mallayasamy S.R. ,Mangasuli S.,Bhat R. A case report of Leptospirosis induced Acute pancreatitis. Journal of Clinical and Diagnostic Research [serial online] 2008 october[cited: 2008 october 6]; 2:1100-1102.
20.Yang R.W., Shao Z.X., Chen Y.Y., Yin Z., Wang W.J. Lipase and pancreatic amylase activities in diagnosis of acute pancreatitis in patients with hyperamylasemia.Hepatobiliary Pancreat Dis Int. 2005 Nov;4(4):600- 603.
21.Domènech Calvet J., Sánchez Cano J.J., Sánchez Marín A., Sánchez Pérez J., Guspí Saiz F, Bertran Llusà N, del Castillo Déjardin D., Macroamylasemia in the differential diagnosis of acute pancreatitis. Revista Clinica Espanola. 1999 Jul;199(7):440-441
22.Edwards C.N., Evarard C.O.R.. Hyperamylasemia and pancreatitis in leptospirosis. Am J Gastroenterol 1991; 86:1665–1668.
23.Kameya S, Hayakawa T, Kemaye A, Wtarabe T. Hyperamylasemia in patients at an intensive care unit. J Clin Gastroenterol 1986;8: 438-442.
24.Cengiz K, Sahan C, Sunbul M, Leblebicioglu H, Cuner E. Acute renal failure in leptospirosis in the black- sea region in Turkey. Int Urol Nephrol 2002;33: 133–136.
25.Isogai M, Yamagychi A, Nakano S. Hepatic histopathological changes in biliary pancreatitis. Am J Gastroenterol 1995;90: 449-454.
26.P Baburaj, T Antony, Francy Louis, BL Harikrishnan. Acute abdomen due to acute pancreatitis- a rare presentation of leptospirosis. J Assoc physicians India. 2008 Nov;56:911-912.
This research work was presented in the 45th APACPH conference 2013, which was held from 24th to 27th October 2013, at Wuhan University, Wuhan, China.
Article citation:
Abul Fazil, Sheetal Ra M, Aditya Verma, Jagadish Rao Padubidri. Hyperamylasemia as an indicator of Acute Pancreatitis in Severe Leptospirosis- A preliminary study. J Pharm Biomed Sci 2014; 04(04):273-278. Available at www.jpbms.info.
Source of support: None
Competing interest / Conflict of interest
The author(s) have no competing interests for financial support, publication of this research, patents and royalties through this collaborative research. All authors were equally involved in discussed research work. There is no financial conflict with the subject matter discussed in the manuscript.
Copyright © 2014 Abul Fazil, Sheetal Raj M, Aditya Verma, Jagadish Rao Padubidri. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited